

(19) (KR)
(12) (A)

(51) . Int. Cl.7 (11) 10-2004-0058201
A61K 31/505 (43) 2004 07 03

(21) 10-2004-7005585
(22) 2004 04 16
2004 04 16
(86) PCT/SE2002/001911 (87) WO 2003/032995
(86) 2002 10 18 (87) 2003 04 24

(30) 0103509-6 2001 10 19 (SE)

(71) 151 85

(72) , - 15185

19850-5437 . . . 15437

19850-5437 . . 15437

(74)

(54)

5,260,440 1 7

$$[(E)-7-[4-(4-6-)]-6-,-2-[()]-5-]-(3R,5S)-3,5-5,260,$$

berg et al., DA. Statins and the Risk of Dementia *Lancet* 356:1627-1631 (November 11, 2000)
 astatin) (Lov
 [*Am J. Med.* 2000;108:538-547 (2000)] 542 ,

[Zorn

(Lov
 가

(AD),

(MCI) MCI 가

[Petersen, et al., *Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)* , Neurology, 56:1133-1142 (2001)] MCI
 : 1) ;
 2) ; 3) ;
 4) ; 5)

(AACD)가

[K. Ritchie et al., *Classification criteria for mild cognitive impairment: A population-based validation study* , Neurology 56:37-42 (2001)]. 40 Ritchie AACD
 가

: 1)

; 2)

2

; 3)

: 3

(Global Deterioration Scale, GDS); 4) DSM-III-R

[Graham et al., *Prevalence and severity of cognitive impairment with and without dementia in an elderly population* , Lancet 349:1793-6 (1997)]

[Wentzel et al., *Progression of impairment in patients with vascular cognitive impairment without dementia* , Neurology 2001;57:714-6 (2001)]
 가 , 가 46%가 CIND

가

()

가 () 가)

가
PCT WO 01/54668
0.5 1 100 mg/ 1 80 mg/ 0.5 200 mg/
0.5 50 mg/ 1 1 1 80 mg

가 2 20 mg/kg (MCAO) () 14 가 eNOS

[M. Endres et al., *Stroke protection by 3-hydroxy- 3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase*, Proc. Natl. Acad. Sci. U S A, 95:8880-8885 (1998)]

(VAD)

가
(eNOS)
(NO) NO eNOS
가
fAD (APP) -1 (PS-1) (A)
A () (fAD) (AD) (A)
A
AD
AD/VAD
VAD, AD,
AD/VAD

-1) LRP-1 A A
-1가 ApoE ApoE4 LRP-1 E (ApoE) -2 A
-1 A , A LRP-1
-1 , LRP-1/ApoE AD (SRE1) AD
A , SRE A LRP-1 mRNA
A
A , LRP-1 A
A ApoE/LRP-1 A LRP-1/ApoE A
A
LRP-1
A ApoE

A (HMG-CoA)

(57)

1.

,

2.

,